Generic Sivextro Availability
Last updated on Apr 10, 2025.
Sivextro is a brand name of tedizolid, approved by the FDA in the following formulation(s):
SIVEXTRO (tedizolid phosphate - powder;intravenous)
-
Manufacturer: CUBIST PHARMS LLC
Approval date: June 20, 2014
Strength(s): 200MG/VIAL [RLD]
SIVEXTRO (tedizolid phosphate - tablet;oral)
-
Manufacturer: CUBIST PHARMS LLC
Approval date: June 20, 2014
Strength(s): 200MG [RLD]
Is there a generic version of Sivextro available?
No. There is currently no therapeutically equivalent version of Sivextro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sivextro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Patent 10,065,947
Issued: September 4, 2018
Inventor(s): Reichenbacher Katharina & Duguid Robert J. & Ware Jacqueline A. & Phillipson Douglas
Assignee(s): Merck Sharp & Dohme Corp.A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as and Clostridia, and acid-resistant microorganisms such as and . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
Patent expiration dates:
- February 3, 2030✓
- February 3, 2030
-
Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Patent 10,442,829
Issued: October 15, 2019
Inventor(s): Reichenbacher Katharina & Duguid Robert J. & Ware Jacqueline A. & Phillipson Douglas
Assignee(s): Merck Sharp & Dohme Corp.A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as and Clostridia, and acid-resistant microorganisms such as and . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
Patent expiration dates:
- February 3, 2030✓
- February 3, 2030
-
Oxazolidinone derivatives
Patent 7,816,379
Issued: October 19, 2010
Inventor(s): Rhee; Jae Keol et al.
Assignee(s): Dong-A Pharm. Co., Ltd. (Seoul, KR)The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Patent expiration dates:
- June 20, 2028✓✓✓
- June 20, 2028
-
Oxazolidinone derivatives
Patent 8,420,676
Issued: April 16, 2013
Inventor(s): Rhee Jae Keol & Im Weon Bin & Cho Chong Hwan & Choi Sung Hak & Lee Tae Ho
Assignee(s): Dong-A Pharmaceuticals Co. Ltd.The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as, Staphylococci, Enterococci and Streptococci anaerobic microorganisms such as and Clostridia, and acid-resistant microorganisms such as and . Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Patent expiration dates:
- February 23, 2028✓✓✓
- February 23, 2028
-
Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Patent 8,426,389
Issued: April 23, 2013
Inventor(s): Reichenbächer Katharina & Duguid Robert J. & Ware Jacqueline A. & Phillipson Douglas
Assignee(s): Trius Therapeutics, Inc.A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi , anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
Patent expiration dates:
- December 31, 2030✓✓✓
- December 31, 2030
-
Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Patent 9,624,250
Issued: April 18, 2017
Inventor(s): Reichenbacher Katharina & Duguid Robert J. & Ware Jacqueline A. & Phillipson Douglas
Assignee(s): Merck Sharp & Dohme Corp.A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as and , anaerobic microorganisms such as and , and acid-resistant microorganisms such as and . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
Patent expiration dates:
- February 3, 2030✓✓✓
- February 3, 2030
-
Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Patent 9,988,406
Issued: June 5, 2018
Inventor(s): Reichenbacher Katharina & Duguid Robert J. & Ware Jacqueline A. & Phillipson Douglas
Assignee(s): Merck Sharp & Dohme Corp.A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as and Clostridia, and acid-resistant microorganisms such as and . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
Patent expiration dates:
- February 3, 2030✓
- February 3, 2030
More about Sivextro (tedizolid)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: oxazolidinone antibiotics
- Breastfeeding
- En español
Patient resources
- Sivextro drug information
- Sivextro (Tedizolid Intravenous) (Advanced Reading)
- Sivextro (Tedizolid Oral) (Advanced Reading)
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.